Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C5H10O5 |
| Molecular Weight | 150.1301 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@@H](O)C=O
InChI
InChIKey=PYMYPHUHKUWMLA-LMVFSUKVSA-N
InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4+,5-/m0/s1
D-ribose, a naturally occurring pentose carbohydrate, and a key component in the adenosine triphosphate (ATP) molecule. D-ribose was studied for congestive heart failure. In addition was discovered, that D-ribose significantly reduced clinical symptoms in patients suffering from fibromyalgia and chronic fatigue syndrome. Recently was published an article where were described, that d-Ribose reacted with the N-terminal valinyl residues of hemoglobin (Hb), thus producing glycated hemoglobin (HbA1c). It is known, that HbA1c is the most important marker of hyperglycemia in diabetes mellitus, which prompts future studies to explore whether D-ribose could also lead to diabetic complications.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095168 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29033370 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The effect of ribose pre-treatment of cortical bone on γ-irradiation sterilization effectiveness. | 2017-12 |
|
| d-Ribose as a Contributor to Glycated Haemoglobin. | 2017-11 |
|
| D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. | 2015-06 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25701016
oral D-ribose (5 g/dose) for 6 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29033370
D-ribose (0.5 mM) was added to foetal calf serum or human urine at 37 °C, and aliquots were collected and used for measurement of D-ribose at different time intervals (0, 2, 4, 6, 8, 24, 36, 48, and 72 h). Haemoglobin (10 mg/ml) was incubated with different concentrations of D-ribose (0, 1, 20, 50, 100, and 200 mM) for 5 days, and aliquots were collected and used for the detection of HbA1c each day. Haemoglobin (10 mg/ml) was incubated with 0.2 mM D-ribose or 7 mM D-glucose (0, 6, 12, 24, 36, 48, 72, and 96 h), and aliquots were collected and used for detection of HbA1c at each interval. HbA1c was determined with an ELISA kit for human HbA1c. D-ribose reacted with the N-terminal valinyl residues of Hb, thus producing significantly higher HbA1c levels (P < 0.001) than D-glucose after three days of incubation with 0.1 M D-ribose or 0.1 M D-glucose. This result demonstrated that both D-ribose and D-glucose glycate Hb and produce HbA1c.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
2926-4
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
||
|
DSLD |
1711 (Number of products:221)
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
||
|
NCI_THESAURUS |
C68484
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
||
|
DSLD |
712 (Number of products:2)
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
||
|
LOINC |
32268-5
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID6043917
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
SUB128226
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
RIBOSE
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
200-059-4
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
681HV46001
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
27476
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
SUB32509
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
100
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
243
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
10257-32-6
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
ALTERNATIVE | |||
|
47013
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
47014
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
613-83-2
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
ALTERNATIVE | |||
|
1603108
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
5311110
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
33942
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
1314858
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
50-69-1
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
681HV46001
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
DB15073
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
100000124325
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
16988
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
m9598
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
C68487
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY | |||
|
45506
Created by
admin on Mon Mar 31 17:54:25 GMT 2025 , Edited by admin on Mon Mar 31 17:54:25 GMT 2025
|
PRIMARY |
ACTIVE MOIETY